| Website | esperancepharma.com |
| Category | BioTech |
| Phone | 225-615-8944 |
| Employees |
| TOTAL | $7.5M |
| VENTURE FUNDING TOTAL | $7.5M |
| Series B, 6/11 Louisiana Fund I Themelios Ventures Advantage Capital Partners Louisiana Technology Innovation Fund | $7.5M |
Esperance Pharmaceuticals is developing a new class of targeted anticancer drugs that selectively kill cancer cells without harming normal cells. Targeting occurs through binding to specific receptors on the cell’s surface. The drugs kill even those cells known to be resistant to chemotherapeutic drugs.
